The Asian Age

Put politics, profit aside; level with all on vaccine

-

India is at present in the midst of one of the largest public health campaigns the world has ever seen: Vaccinatio­n against Covid-19 pandemic. Its first phase, which started on January 16, seeks to inoculate three crore Covid warriors including medical profession­als and frontline workers. Initial reports suggest that the response to the programme has not been all that encouragin­g and there exists some reluctance, if not resistance, in taking the jab.

Addressing a public health issue is as much the job of the public as that of the government, and the programme should have received a wholeheart­ed welcome since the target group is very much part of the system that fights the pandemic. That has not happened, and the government needs to assess its reasons. While doing so, it must bear in mind two things: one; lack of transparen­cy in the whole exercise, and two, technical glitches in the CoWIN app that monitors it.

Prime Minister Narendra Modi misses no opportunit­y to stress that the two vaccines that are being used for the programme are made in India. However, there have been doubts even among health profession­als about the suitabilit­y of introducin­g Covaxin, the indigenous­ly developed and manufactur­ed vaccine, in the programme since it has been cleared only for phase III of the clinical trial. Now, days after the programme has started, and after lakhs of people have taken their vaccines, the two companies that manufactur­e the vaccines have come out with advisories to the people. They contain certain precaution­s those who go for them must take, including an advice that people with certain medical conditions should avoid taking them.

This late realisatio­n, if one may call it so, is grossly unacceptab­le. The government and the companies should have been upfront about the products from the beginning, instead of resorting to chest-thumping about their being made-in-India. Nobody has a doubt about the capabiliti­es of Indian scientists or Indian manufactur­ers: the latest Lancet reports underscore­s the efficacy of the vaccine, and says all adverse events were mild and moderate and were more frequent after the first dose. But the fact remains that the scientific process should be allowed to be completed in its entirety; political and commercial considerat­ions should wait for their turn. The government must at least now do a rethink on the campaign and be true and honest with the people on its components. It must win people’s confidence by placing all the facts before them, to start with; piecemeal and ad hoc release of critical informatio­n is not the right way to do it.

Technical glitches hampering the vaccinatio­n programme equally defy logic. The government had ample time to develop a proper, fool-proof mechanism for it but its performanc­e on this front has been dismal. Similar was the case with Aarogya Setu, the app that helps people follow Covid-appropriat­e protocol. The government must ensure that such mass programmes are designed with little technical interface, realising the fact that a great share of the Indian population has little access to technology products. And when used, they should come without glitches and in an easy-to-use form. The government must realise that this is a fight India can ill-afford to lose.

The government must win people’s confidence by placing all the facts before them, to start with; piecemeal and ad hoc release of critical informatio­n is not the right way to do it

Newspapers in English

Newspapers from India